DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

Author(s): Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, On behalf of the Parkinson's Disease Research Group of the United Kingdom

Affiliation(s): From National Hospital for Neurology and Neurosurgery (R.K., A.E., A.J.L.), London; Reta Lila Weston Institute of Neurological Studies (R.K., A.E., A.J.L.), and Department of Epidemiology and Public Health (J.H.), University College London; Department of Neurology (R.K.), Donauspital/SMZ-Ost, Vienna, Austria; University Department of Clinical Neurosciences (A.S.), Royal Free and University College Medical School, London; and Department of Social Medicine (Y.B.-S.), University of Bristol, UK.

Publication date & source: 2008-06-25, Neurology., [Epub ahead of print]

BACKGROUND: Ten-year follow-up results from the PD Research Group of the United Kingdom trial demonstrated that there were no long-term advantages to initiating treatment with bromocriptine compared with L-dopa in early Parkinson disease (PD). Increased mortality in patients on selegiline combined with L-dopa led to premature termination of this arm after 6 years. METHODS: Between 1985 and 1990, 782 patients were recruited into an open pragmatic multicenter trial and were randomized to L-dopa/decarboxylase inhibitor (DDCI), L-dopa/DDCI plus selegiline, or bromocriptine. The main endpoints were mortality, disability, and motor complications. For final follow-up, health-related quality of life and mental function were also assessed. RESULTS: Median duration of follow-up at final assessment was 14 years in the 166 (21%) surviving participants who could be contacted. After adjustment for baseline characteristics, disability scores were better in the L-dopa than in the bromocriptine arm (Webster: 16.6 vs 19.8; p = 0.03; Northwestern University Disability: 34.3 vs 30.0, p = 0.05). Physical functioning (difference 20.8; 95% CI 10.0, 31.6; p < 0.001) and physical summary scores (difference 5.2; 95% CI 0.7, 9.7; p = 0.03) on the 36-item short-form health survey were also superior on L-dopa. Differences in mortality rates and prevalence of dyskinesias, motor fluctuations, and dementia were not significantly different. CONCLUSION: Initial treatment with the dopamine agonist bromocriptine did not reduce mortality or motor disability and the initially reduced frequency in motor complications was not sustained. We found no evidence of a long-term benefit or clinically relevant disease-modifying effect with initial dopamine agonist treatment.

Page last updated: 2008-08-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017